229 related articles for article (PubMed ID: 22149470)
1. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome.
Green T; Weinberger R; Diamond A; Berant M; Hirschfeld L; Frisch A; Zarchi O; Weizman A; Gothelf D
J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):589-95. PubMed ID: 22149470
[TBL] [Abstract][Full Text] [Related]
2. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
[TBL] [Abstract][Full Text] [Related]
4. Clinically-oriented monitoring of acute effects of methylphenidate on cerebral hemodynamics in ADHD children using fNIRS.
Monden Y; Dan H; Nagashima M; Dan I; Kyutoku Y; Okamoto M; Yamagata T; Momoi MY; Watanabe E
Clin Neurophysiol; 2012 Jun; 123(6):1147-57. PubMed ID: 22088661
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
[TBL] [Abstract][Full Text] [Related]
7. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
8. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
[TBL] [Abstract][Full Text] [Related]
9. Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II--broader executive and non-executive domains.
Rhodes SM; Coghill DR; Matthews K
J Child Psychol Psychiatry; 2006 Nov; 47(11):1184-94. PubMed ID: 17076758
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate dosing: twice daily versus three times daily.
Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
[TBL] [Abstract][Full Text] [Related]
11. Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder.
Salatino-Oliveira A; Genro JP; Zeni C; Polanczyk GV; Chazan R; Guimarães AP; Callegari-Jacques SM; Rohde LA; Hutz MH
Biol Psychiatry; 2011 Aug; 70(3):216-21. PubMed ID: 21550019
[TBL] [Abstract][Full Text] [Related]
12. Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder.
Cheon KA; Jun JY; Cho DY
Int Clin Psychopharmacol; 2008 Sep; 23(5):291-8. PubMed ID: 18703939
[TBL] [Abstract][Full Text] [Related]
13. Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD.
Pearson DA; Santos CW; Casat CD; Lane DM; Jerger SW; Roache JD; Loveland KA; Lachar D; Faria LP; Payne CD; Cleveland LA
J Am Acad Child Adolesc Psychiatry; 2004 Jun; 43(6):677-85. PubMed ID: 15167084
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of methylphenidate on performance during the Test of Variables of Attention in children with attention deficit/hyperactivity disorder.
Huang YS; Chao CC; Wu YY; Chen YY; Chen CK
Psychiatry Clin Neurosci; 2007 Jun; 61(3):219-25. PubMed ID: 17472588
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
[TBL] [Abstract][Full Text] [Related]
16. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD.
Handen BL; Feldman HM; Lurier A; Murray PJ
J Am Acad Child Adolesc Psychiatry; 1999 Jul; 38(7):805-12. PubMed ID: 10405497
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
19. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
[TBL] [Abstract][Full Text] [Related]
20. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
